ERB-196
ERB-196, also known as WAY-202196, is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.[1][2][3][4][5][6] It possesses 78-fold selectivity for the ERβ over the ERα.[1] The drug was under development by Wyeth for the treatment of inflammation and sepsis starting in 2004 but development was discontinued by 2011.[2][7]
 | |
| Clinical data | |
|---|---|
| Other names | WAY-202196 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H10FNO2 |
| Molar mass | 279.270 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- R. E. Hubbard (2006). Structure-based Drug Discovery: An Overview. Royal Society of Chemistry. pp. 241–. ISBN 978-0-85404-351-4.
- Estrogens—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 21 June 2013. pp. 52–. ISBN 978-1-4816-8771-3.
- Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 66–. ISBN 978-3-527-62330-3.
- Mewshaw RE, Edsall RJ, Yang C, Manas ES, Xu ZB, Henderson RA, Keith JC, Harris HA (2005). "ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity". J. Med. Chem. 48 (12): 3953–79. doi:10.1021/jm058173s. PMID 15943471.
- Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC, Harris HA (2006). "WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock". Crit. Care Med. 34 (8): 2188–93. doi:10.1097/01.CCM.0000227173.13497.56. PMID 16755255. S2CID 20876539.
- Jean-Louis Vincent (8 December 2007). Yearbook of Intensive Care and Emergency Medicine 2007. Springer Science & Business Media. pp. 891–. ISBN 978-3-540-49433-1.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.